Canaccord raised the firm’s price target on CervoMed (CRVO) to $21 from $12 and keeps a Buy rating on the shares. The firm noted they reported Q4 results and said the key update was that the company is on track to report 32-week open-label extension (OLE) data from its Phase 2b trial for neflamapimod for dementia with Lewy bodies (DLB) in 2H25, and based on interactions with regulatory bodies, expects to start a Phase 3 trial in mid-2026.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVO:
- Cervomed Inc. Faces Financial Hurdles Due to Regulatory Restrictions on Public Float
- CervoMed reports FY24 EPS ($2.02), consensus ($1.85)
- CervoMed sees cash runway into mid-2026
- Capital One, CervoMed, HPE, Eaton, PepsiCo: Trending by Analysts
- CervoMed upgraded to Buy at JonesResearch on more confidence in DLB program
Questions or Comments about the article? Write to editor@tipranks.com